Authors
Latest:
Value-Based Purchasing for Prescription Drugs Takes a Leap Forward in State MedicaidThe U.S. Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) are commitment to support value-based purchasing (VBP) of prescription drugs in Medicaid, despite headlines of CMS’s rejection of a Massachusetts request to make changes in its Medicaid prescription drug benefit.
Latest:
Pathways to Potential in Europe's Pharmerging MarketsFilip Conic outlines the market-access approaches and commercial strategies to unlock the growth potential in the Southeastern and Eastern European region.
Latest:
Patient Communications: Why Pharma Leaders Should Think Like Social MarketersBy exploring how social marketers think, pharma can unlock tried-and-tested ways to bring measurable value to their patients, writes Patrick Ladbury and Oliver Childs.
Latest:
Early-Development Strategy for PTE in Biologics Given Unknowns in the LawThe importance of early development strategy and planning for biologic patent term extension.
Latest:
A Seat at the Strategy TableHow navigating compliance risks requires so much more than policies and procedures.
Latest:
Patient & Customer-Centric CommercializationOutlining a real-world example in which building and operationalizing a patient- and customer-centric commercialization strategy drove a successful launch from a “standing start.”
Latest:
Patient & Customer-Centric CommercializationOutlining a real-world example in which building and operationalizing a patient- and customer-centric commercialization strategy drove a successful launch from a “standing start.”
Latest:
Patient & Customer-Centric CommercializationOutlining a real-world example in which building and operationalizing a patient- and customer-centric commercialization strategy drove a successful launch from a “standing start.”
Latest:
Early-Development Strategy for PTE in Biologics Given Unknowns in the LawThe importance of early development strategy and planning for biologic patent term extension.
Latest:
EMA Relocation Countdown: Some Industry ViewpointsRaman Sehgal talks to three industry leaders for their insights on the challenges faced across the life science sector and how the EMA needs to respond.
Latest:
The Key to Better Navigating VUCA Industry ConditionsAlison Horstmeyer discusses how pharma executives can apply four attributes of curiosity to negotiate VUCA (volatile, uncertain, complex, and ambiguous) conditions and improve organizational outcomes.
Latest:
Does the Pfizer Restructuring Make Sense?The Pfizer restructuring will be a case study in whether corporate restructuring & innovation can co-exist or whether M&A is the more viable answer, writes Edward Pratesi.
Latest:
Five Measures to Cope with the Side Effects of Health ReformWith more than 8 million Americans now signed up for health insurance through state health exchanges, The Affordable Care Act (ACA) has begun delivering benefits and new insurance protections to a large swath of Americans, many of whom had no health insurance before.
Latest:
Pharma AI Requires a New Approach to GovernanceArtificial intelligence adoption by pharma companies in the UK demands a new, agile governance layer, write Tim Wright and Antony Bott.
Latest:
Optimizing the Digital Opportunity in Biopharmaceutical R&DIf advanced technologies hold the key to at least some of the productivity issues R&D organizations need to overcome, Nicholas Lakin asks what are the best strategies and operating models for exploiting these aids to their fullest potential.
Latest:
Hitting Your Targets: A Check-up on DataProvider data delivers insights into customers and drives decisions about where to focus resources, providing opportunities for sales and marketing in life sciences.
Latest:
3 Cash-Saving Hacks for the Pharmaceutical IndustryA list of four ways the pharma industry can save money on travel-related employee expenses regarding VAT on clinical trials, clinical trial supplies, sourcing, and more.
Latest:
Hitting Your Targets: A Check-up on DataProvider data delivers insights into customers and drives decisions about where to focus resources, providing opportunities for sales and marketing in life sciences.
Latest:
Cross-Border Funding in the Life SciencesRecord capital flows across global public and private markets has opened up new channels of investment in early-stage and novel science.
Latest:
‘Emerging’ Product Launch StrategiesCommercial leaders can boost product launches with a data-driven roadmap.
Latest:
What Issues Are Top of Mind for Smaller Biotech and Emerging Biopharma Companies?Daniel Patrick discusses the small biotech company journey from an incubator of ideas to the ability to shepherd an R&D asset through its pipeline to achieving commercial success.
Latest:
Linguistic Validation: Amplifying the Patient VoiceDesigning and managing clinical outcome assessments on an international basis is more than a translation task. It requires the more discrete practice of linguistic validation, writes Dana Weiss.
Latest:
Leading Courageously and Bringing Others Along In an Evolving Healthcare EnvironmentTo be successful, healthcare organizations must delve into optimizing leadership skills and building a deep pipeline of executive-ready talent.
Latest:
CEO Spills the Secret to Attracting, Retaining Biotech TalentOne of the most important jobs of a biotech executive is building a strong team that will not only keep a company competitive in the current market, but will also have the stamina to carry it into the future.
Latest:
3 Tips for Successful Public-Private Partnerships in HealthcareA list of three key elements when looking at public-private partnerships to tackle public health challenges.
Latest:
Army Leadership Lessons: Develop Leaders Three Levels DownChad Storlie draws on military training to outline how all industries and organisations can create great junior leaders.
Latest:
Emerging Collaboration in EU Drug Pricing and Reimbursement: A Beneluxa Case StudyMaude Schmidt and Giovanni Saldutti look at the intergovernmental initiatives involving joint price negotiations developed across Europe as the Beneluxa Initiative on Pharmaceutical Policy to explore the outcomes and implications from these alliances.
